Avant Technologies and Partner, Ainnova, Finalizing Automated Retinal Camera Prototype Ahead of Full-Scale Development
LAS VEGAS, NEVADA / ACCESS Newswire / June 10, 2025 / Avant Technologies Inc. (OTCQB:AVAI) ("Avant" or the "Company"), and its JV partner, Ainnova Tech, Inc., (Ainnova), a leading healthcare technology company focused on revolutionizing early disease detection using artificial intelligence (AI), today announced the Company is in the final stages of prototyping its proprietary automated retinal camera. Ainnova's new device will offer users a low cost, easier to use camera that captures images automatically and then uploads those images to the Company's Vision AI software platform, which then produces a "risk report" in mere seconds.
Vinicio Vargas, Chief Executive Officer at Ainnova and member of the Board of Directors of the joint venture company, Ai-nova Acquisition Corp., said, "The cost of a fundus camera has always been a barrier to entry into in this market, so our low-cost camera, which is a fraction of the cost of currently available cameras on the market, should allow us to not only enter the market, but to capture a large share of the market.
"Another significant advantage will be that our camera will be seamlessly packaged together with our Vision AI platform, allowing us to refer more patients in less time and accurately to medical specialists. Also, one of our objectives is to integrate other technologies to this preventive screening, expanding the scope from only diabetic patients to patients who have other risk factors and want to prevent other diseases from a more complete approach."
Vision AI is a powerful cutting-edge, AI-driven platform that can quickly and accurately detect the early markers of a host of diseases by applying AI models to examine imaging data from the eye to expedite earlier detection and allow patients to better manage their disease. The diseases that Vision AI can detect, include diabetic retinopathy, other retinopathies, such as glaucoma, macular edema, age-related macular degeneration, and other anomalies, as well as other diseases that do not require retinal images, and instead, use other datapoints that Ainnova has integrated into the software like the detection of cardiovascular disease (CVD), type 2 diabetes, liver fibrosis, and chronic kidney disease (CKD).
Currently, Ainnova's Vision AI software works well with any fundus camera on the market; however, Ainnova and Avant are aiming for exclusivity by developing a lower-cost, easier to use camera.
Ai-nova Acquisition Corp. (AAC), the company formed by the partnership between Avant and Ainnova, will develop the retinal cameras as part of the joint venture and licensing deal to facilitate the development of Ainnova's technology portfolio. AAC owns the global licensing rights to develop, maintain, and market Ainnova's technology portfolio.
About Ainnova Tech, Inc.
Ainnova is a Nevada-based healthtech startup with headquarters in San Jose, Costa Rica, and Houston, Texas. Founded by an experienced and innovative team that is dedicated to leveraging artificial intelligence for early disease detection. Recognized with multiple global awards and renowned partnerships with hospitals and medical device companies, we proudly introduce Vision AI - our cutting-edge platform designed to prevent blindness and detect the early onset of diabetes. Explore how Ainnova is revolutionizing healthcare through advanced technology and proactive solutions.
About Avant Technologies Inc.
Avant Technologies Inc. is an emerging technology company developing solutions in artificial intelligence in healthcare. With a focus on pushing the boundaries of what is possible in AI and machine learning, Avant serves a diverse range of industries, driving progress and efficiency through state-of-the-art technology.
More information about Avant can be found at https://avanttechnologies.com
You can also follow us on social media at:
https://twitter.com/AvantTechAI
https://www.linkedin.com/company/avant-solutionspr/
https://www.facebook.com/AvantTechAI
https://www.youtube.com/@AvantTechAI
Forward-Looking Statements
Certain statements contained in this press release may constitute "forward-looking statements." Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements because of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (http://www.sec.gov). In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, governmental and public policy changes, the Company's ability to raise capital on acceptable terms, if at all, the Company's successful development of its products and the integration into its existing products and the commercial acceptance of the Company's products. The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date after the date of the press release.
Contact:
Avant Technologies Inc.info@avanttechnologies.com
SOURCE: Avant Solutions
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
33 minutes ago
- Yahoo
National Fuel Increases Dividend Rate for 55th Consecutive Year
WILLIAMSVILLE, N.Y., June 12, 2025 (GLOBE NEWSWIRE) -- Today, the National Fuel Gas Company ("National Fuel" or the "Company") (NYSE: NFG) Board of Directors approved a 3.9% increase in the dividend on the Company's common stock, raising the quarterly rate from 51.5 cents per share as approved in June 2024 to 53.5 cents per share for an annual rate of $2.14 per share. National Fuel has paid dividends for 123 consecutive years and has increased its annual dividend for 55 straight years. This dividend is payable July 15, 2025, to stockholders of record at the close of business on June 30, 2025. The Company has approximately 90.4 million shares of common stock outstanding. It has no preferred stock outstanding. National Fuel is a diversified energy company headquartered in Western New York that operates an integrated collection of natural gas assets across four business segments: Exploration & Production, Pipeline & Storage, Gathering, and Utility. Additional information about National Fuel is available at CONTACT: Investor Contact: Natalie Fischer | 716-857-7315 Media Contact: Karen Merkel | 716-857-7654Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
34 minutes ago
- Yahoo
Robotic Pet Company Tombot Secures $6.1M Series A Funding to Support Groundbreaking Health and Senior Care Product Line
LOS ANGELES, June 12, 2025--(BUSINESS WIRE)--Tombot, the robotics company that earned widespread acclaim at CES earlier this year for its lifelike robotic puppy, Jennie, announced today the successful close—and oversubscription—of its $6.1 million Series A funding round. "Tombot is entering a high-demand, underserved market at the intersection of mental health and assistive technology," said Tombot CEO and Co-Founder Tom Stevens. "Over 300 million seniors around the world with dementia and mild cognitive impairment are unable to care for a live animal at a time when they need the companionship of a pet more than ever. Millions of other individuals suffering from mental health adversities are in a similar predicament." With artistic design by Jim Henson's Creature Shop, and developed with the guidance of clinical experts, patients, and their families, Jennie provides many of the health benefits associated with live animal ownership, such as reduced stress and loneliness. Jennie will be used in private homes, assisted living and memory care communities, and other settings where live animals are not always safe or practical. Covered with sensors to respond to touch, voice commands, movement, and other sensory inputs, Jennie is rechargeable, fully cleanable, and comes with an optional caregiver app to customize behaviors and ease the burden of caregiving. With participation from both new and existing investors, the funding round was led by Caduceus Capital Partners, a Nashville-based team of veteran healthcare investors with a primary emphasis on accelerating growth of early-stage digital health startups. "We identified the growing need for robotic companions several years ago and believe the market is now on the brink of exponential expansion," said Dave Vreeland, senior managing partner, Caduceus Capital Partners. "By 2030, the U.S. is projected to have 73 million seniors – an aging population that will increasingly face challenges related to loneliness, companionship, and chronic disease management. These issues are rapidly surpassing the capacity of human caregivers alone. Tombot is uniquely positioned to lead this emerging sector and drive widespread adoption of robotic companions." "This investment will be rocket fuel for Tombot," said Stevens. "We are most appreciative of our company's Board of Directors for their ongoing guidance, and are especially grateful to Caduceus for recognizing and supporting Tombot's mission of creating robotic animals that transform the daily lives of individuals, families, and communities facing health adversities." According to Stevens, this milestone investment will be used to expand Tombot's team, finalize engineering, complete regulatory and safety certifications, and prepare its first robotic pet for customer shipments to its more than 16,000 pre-order and waitlist customers. About Tombot Tombot, Inc., established in 2017, designs realistic robotic companion animals for individuals unable to safely or practically care for a live animal. After Tom Stevens' own mother's progressive dementia necessitated the rehoming of her beloved pet dog for safety reasons, Tom launched Tombot. Tombot's flagship product, Jennie, was designed specifically to treat the Behavioral and Psychological Symptoms of Dementia (BPSD). The Tombot founding team built a prior startup into one of the world's largest legal automation companies and was successfully acquired. View source version on Contacts Media Contacts: Brotman•Winter•Fried Consulting Laura Runcielaura@ (201)707-9372 Steve Winterswinter@ (202) 468-8100
Business Wire
37 minutes ago
- Business Wire
Robotic Pet Company Tombot Secures $6.1M Series A Funding to Support Groundbreaking Health and Senior Care Product Line
LOS ANGELES--(BUSINESS WIRE)-- Tombot, the robotics company that earned widespread acclaim at CES earlier this year for its lifelike robotic puppy, Jennie, announced today the successful close—and oversubscription—of its $6.1 million Series A funding round. Tombot's flagship product, Jennie, was designed specifically to treat the Behavioral and Psychological Symptoms of Dementia (BPSD) and other health issues. 'Tombot is entering a high-demand, underserved market at the intersection of mental health and assistive technology,' said Tombot CEO and Co-Founder Tom Stevens. 'Over 300 million seniors around the world with dementia and mild cognitive impairment are unable to care for a live animal at a time when they need the companionship of a pet more than ever. Millions of other individuals suffering from mental health adversities are in a similar predicament.' With artistic design by Jim Henson's Creature Shop, and developed with the guidance of clinical experts, patients, and their families, Jennie provides many of the health benefits associated with live animal ownership, such as reduced stress and loneliness. Jennie will be used in private homes, assisted living and memory care communities, and other settings where live animals are not always safe or practical. Covered with sensors to respond to touch, voice commands, movement, and other sensory inputs, Jennie is rechargeable, fully cleanable, and comes with an optional caregiver app to customize behaviors and ease the burden of caregiving. With participation from both new and existing investors, the funding round was led by Caduceus Capital Partners, a Nashville-based team of veteran healthcare investors with a primary emphasis on accelerating growth of early-stage digital health startups. 'We identified the growing need for robotic companions several years ago and believe the market is now on the brink of exponential expansion,' said Dave Vreeland, senior managing partner, Caduceus Capital Partners. 'By 2030, the U.S. is projected to have 73 million seniors – an aging population that will increasingly face challenges related to loneliness, companionship, and chronic disease management. These issues are rapidly surpassing the capacity of human caregivers alone. Tombot is uniquely positioned to lead this emerging sector and drive widespread adoption of robotic companions." 'This investment will be rocket fuel for Tombot,' said Stevens. 'We are most appreciative of our company's Board of Directors for their ongoing guidance, and are especially grateful to Caduceus for recognizing and supporting Tombot's mission of creating robotic animals that transform the daily lives of individuals, families, and communities facing health adversities.' According to Stevens, this milestone investment will be used to expand Tombot's team, finalize engineering, complete regulatory and safety certifications, and prepare its first robotic pet for customer shipments to its more than 16,000 pre-order and waitlist customers. About Tombot Tombot, Inc., established in 2017, designs realistic robotic companion animals for individuals unable to safely or practically care for a live animal. After Tom Stevens' own mother's progressive dementia necessitated the rehoming of her beloved pet dog for safety reasons, Tom launched Tombot. Tombot's flagship product, Jennie, was designed specifically to treat the Behavioral and Psychological Symptoms of Dementia (BPSD). The Tombot founding team built a prior startup into one of the world's largest legal automation companies and was successfully acquired.
